Huntsman Cancer Institute at the University of Utah (the U) rang in the new year with new leadership appointments through new roles for Theresa Werner, MD, and Neeraj Agarwal, MD, FASCO. Renowned for ...

Neeraj Agarwal, MD, of the University of Utah's Huntsman Cancer Institute, discusses challenges to progress in getting FDA approval for PARP inhibitors in prostate cancer. FDA approvals for PARP ...

Neeraj Agarwal, MD, of the University of Utah's Huntsman Cancer Institute, discusses ongoing trials of PARP inhibitors as first-line metastatic prostate cancer treatments. There is discussion of ...

Huntsman Cancer Institute at the University of Utah (U of U) announced the appointment of Neeraj Agarwal, MD, physician-scientist at HCI and professor of internal medicine at the U of U, as senior ...

TALAPRO-2, a study led by Neeraj Agarwal, MD, FASCO, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progression or death by 37%. Agarwal, Presidential ...

Neeraj Agarwal is a professor of Medicine and Director of the Genitourinary Oncology Program at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah. This website uses ...

San Francisco-based CRO Vial has beefed up its oncology expertise by adding cancer physician Neeraj Agarwal, M.D., to its scientific advisory board. Vial announced the appointment earlier this month, ...

Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer ...

There are differences in prostate cancer treatment intensification adoption between academic and nonacademic physicians. Findings from the IMPLEMENT sub-analysis investigating patients with metastatic ...